Results 11 to 20 of about 5,420 (200)

Synergistic antifungal activity of antiretrovirals with amphotericin B against Aspergillus species. [PDF]

PLoS ONE
Aspergillosis is a life-threatening fungal infection that primarily affects the lungs of immunocompromised individuals, including those living with human immunodeficiency virus (HIV), and is associated with mortality rates exceeding 50%. The infection is
Ammar A Khan, Ehab A Salama, Mohamed N Seleem   +2 more
doaj   +2 more sources

Determination and Quantification of Related Impurity Substances in Elvitegravir Drug Substance by Full Factorial Design Evaluated Liquid Chromatography Method

Separation Science Plus
Herein, our work deals with developing a rapid, accurate, and reliable high‐performance liquid chromatographic technique with the application of quality by design (QbD) experimental tool to quantify Elvitegravir drug (Integrase inhibitors of ...
Koteswara Rao Vandavasi
exaly   +2 more sources

Formulation and evaluation elvitegravir loaded microspheres

International Journal of Clinical Pharmacokinetics and Medical Sciences
Elvitegravir microspheres have been prepared and evaluated utilising the emulsion solvent diffusion technique as the study's goal. Elvitegravir was made using the emulsion solvent diffusion process and is filled with HPMC and ethyl cellulose microspheres.
{"name":"T Sreeja","email":"sreejasridhar911@gmail.com","affi, {"name":"Yerikala Ramesh","email":"sreejasridhar911@gmail.com","affi, {"name":"Venugopalaiah Penabaka","email":"sreejasridhar911@gmail.com","af, {"name":"Yadala Prapurna Chandra","email":"sreejasridhar911@gmail.   +3 more
semanticscholar   +2 more sources

Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS

HIV/AIDS: Research and Palliative Care, 2014
Krishan K PandeyInstitute for Molecular Virology, Saint Louis University Health Sciences Center, St Louis, MO, USAAbstract: Human immunodeficiency virus type 1 (HIV-1) integrase inhibitors belong to a novel class of antiretroviral drugs with high potency
Pandey KK
doaj   +5 more sources

Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system. [PDF]

HIV Med
Abstract Objective Integrase strand transfer inhibitors (INSTIs) are widely used in antiretroviral therapy (ART) for people with HIV due to their efficacy and tolerability. However, concerns about weight gain and metabolic disturbances have emerged.
Zhang L, Chen L, Tang J, Liu X, Zheng L, Wang F, Huang X, Cao W, Li T.   +8 more
europepmc   +2 more sources

HIV-1 Resistance to Dolutegravir in Benin: The Need to Improve and Strengthen Therapeutic Patient Education Strategies to Achieve the Third Objective 95 of UNAIDS 95-95-95 Target. [PDF]

Case Rep Infect Dis
Benin has adopted the WHO 2019 recommendations by integrating dolutegravir into the first‐ and second‐line treatment regimen with regular monitoring of the emergence of resistance. The standard of care document has been updated, and healthcare staff have been trained on dosage, drug interactions, and the management of adverse effects.
Tchiakpe E, Diop-Ndiaye H, Osawe S, Toure-Kane C, Yessoufou A.   +4 more
europepmc   +2 more sources

Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study

Frontiers in Cellular and Infection Microbiology, 2023
IntroductionSecond-generation integrase strand transfer inhibitors (INSTIs) are preferred treatment options worldwide, and dolutegravir (DTG) is the treatment of choice in resource-limited settings.
José Ramón Santos, Maria Casadellà, Marc Noguera-Julian, Rafael Micán-Rivera, Pere Domingo, Antonio Antela, Joaquin Portilla, Jesús Sanz, Marta Montero-Alonso, Jordi Navarro, Mar Masiá, Mar Masiá, Nieves Valcarce-Pardeiro, Antonio Ocampo, Laura Pérez-Martínez, Coral García-Vallecillos, María Jesús Vivancos, María Jesús Vivancos, Arkaitz Imaz, José Antonio Iribarren, José Hernández-Quero, Judit Villar-García, Pilar Barrufet, Roger Paredes, Roger Paredes, INSTINCT study group, Mariona Perera, Anna Chamorro, Cristina Miranda, Nástor Sánchez, Anna Garcı́á, Núria Pérez, Juan González Garcı́á, María del Mar Gutiérrez, María Gracia Mateo, Elena Losada, Sergio Reus, Vicente Boix, Diego Torrús, Esperanza Merino, Angela Gutiérrez Liarte, Adrià Curran, Félix Gutiérrez, Anna Mariño Callejo, Alvarez Diaz Hortensia, Antonio Ocampo Hermida, Celia Miralles, Laura Labajo Leal, Guillermo Pousada, José Ramon Blanco, José Antonio Oteo, Ibarra Valvanera, Mercedes Sanz, Luis Metola, Juan Pascua, Daniel Podzamczer, Camila Piatti, Maialen Ibarguren, Laia Arbones, Marta Ruiz, Sara Cervanntes, Helena Pera, Jessica Toro, Nuria Perez-Alvarez, Anna Garcia   +64 more
doaj   +1 more source

Anti-HIV drug elvitegravir suppresses cancer metastasis via increased proteasomal degradation of m6A methyltransferase METTL3.

Cancer Research, 2022
N6-methyladenosine (m6A) methylation is an abundant modification in eukaryotic mRNAs. Accumulating evidence suggests a role for RNA m6A methylation in various aspects of cancer biology.
Long Liao, Yan He, Shu Li, Guo Geng Zhang, Wei Yu, Jing Yang, Zi-Jia Huang, Can-Can Zheng, Qing‐Yu He, Yan Li, Bin Li   +10 more
semanticscholar   +1 more source

Extended Postexposure Protection Against Vaginal Simian/Human Immunodeficiency Virus Infection With Tenofovir Alafenamide Fumarate/Elvitegravir Inserts in Macaques

Journal of Infectious Diseases, 2023
Vaginal inserts that can be used on demand before or after sex may be a desirable human immunodeficiency virus (HIV) prevention option for women. We recently showed that inserts containing tenofovir alafenamide fumarate (TAF, 20 mg) and elvitegravir (EVG,
Natalia Makarova, Tyana Singletary, M. Peet, J. Mitchell, S. Bachman, A. Holder, Chuong Dinh, Jonathan T Lipscomb, V. Agrahari, Maria Mendoza, Yi Pan, W. Heneine, M. Clark, J. García-Lerma, Gustavo F. Doncel, James M. Smith   +15 more
semanticscholar   +1 more source

Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens. [PDF]

PLoS ONE, 2012
Human immunodeficiency virus type 2 (HIV-2) is intrinsically resistant to non-nucleoside reverse transcriptase inhibitors and exhibits reduced susceptibility to several of the protease inhibitors used for antiretroviral therapy of HIV-1. Thus, there is a
Robert A Smith, Dana N Raugi, Charlotte Pan, Matthew Coyne, Alexandra Hernandez, Brad Church, Kara Parker, James I Mullins, Papa Salif Sow, Geoffrey S Gottlieb, University of Washington-Dakar HIV-2 Study Group   +10 more
doaj   +1 more source